You are here

Home

Clinical Trials: Lung Disease

Each Clinical Trial will open in a new browser window or tab.

Return to Clinical Trials Page

Posted: Wednesday, July 7, 2021 - 12:00
Application of hUC-MSCs in Treating Acute Lung Injury: a Single Center Prospective Clinical Research
Condition:   Acute Lung Injury
Intervention:   Biological: human derived umbilical cord derived mesenchymal stem cells
Sponsor:   Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting
Posted: Friday, June 11, 2021 - 12:00
A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)
Condition:   Covid19
Interventions:   Drug: ALLOCETRA-OTS;   Other: Placebo
Sponsor:   Enlivex Therapeutics Ltd.
Not yet recruiting
Posted: Wednesday, June 9, 2021 - 12:00
Allogeneic MSC Treatment for Pulmonary Emphysema
Conditions:   Pulmonary Emphysema;   Mesenchymal Stromal Cells
Interventions:   Genetic: Allogeneic MSC;   Drug: Placebo
Sponsors:   Leiden University Medical Center;   Erasmus Medical Center;   VU University Medical Center
Recruiting
Posted: Wednesday, June 2, 2021 - 12:00
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID Acute Respiratory Distress Syndrome
Conditions:   Acute Respiratory Distress Syndrome;   Ards
Interventions:   Biological: COVI-MSC;   Drug: Placebo
Sponsor:   Sorrento Therapeutics, Inc.
Not yet recruiting
Posted: Monday, May 17, 2021 - 12:00
An Phase2 Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection
Condition:   Severe Acute Respiratory Syndrome Coronavirus 2
Interventions:   Biological: Mesenchymal stem cell;   Biological: Placebo
Sponsor:   Rohto Pharmaceutical Co., Ltd.
Not yet recruiting
Posted: Thursday, March 18, 2021 - 12:00
The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19
Conditions:   Pulmonary Fibrosis;   Interstitial Lung Disease;   Covid19
Intervention:   Biological: MON002
Sponsors:   Guy's and St Thomas' NHS Foundation Trust;   King's College London
Recruiting
Posted: Monday, March 15, 2021 - 12:00
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
Conditions:   Covid19;   Novel Coronavirus Pneumonia;   Acute Respiratory Distress Syndrome
Interventions:   Drug: MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8);   Drug: MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8);   Drug: MSC-exosomes delivered intravenously every other day (8:8:8)
Sponsor:   AVEM HealthCare
Not yet recruiting
Posted: Wednesday, February 3, 2021 - 12:00
Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome
Conditions:   Acute Respiratory Distress Syndrome;   Covid19
Intervention:   Biological: T regulatory cells
Sponsor:   Stanford University
Not yet recruiting
Posted: Wednesday, January 20, 2021 - 12:00
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
Conditions:   Covid19;   Sars-CoV-2 Infection;   ARDS, Human;   Severe covid19
Interventions:   Combination Product: autologous activated platelet-rich plasma;   Drug: Avigan
Sponsors:   Hayandra Peduli Foundation;   Koja Regional Public Hospital
Recruiting
Posted: Monday, November 16, 2020 - 12:00
Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Longeveron Mesenchymal Stem Cells (LMSCs) (RECOVER)
Conditions:   ARDS, Human;   Covid19
Interventions:   Biological: Longeveron Mesenchymal Stem Cells (LMSCs);   Other: Placebo
Sponsor:   Longeveron LLC
Recruiting

Pages